These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16718472)

  • 1. Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients.
    Zippelius A; Gati A; Bartnick T; Walton S; Odermatt B; Jaeger E; Dummer R; Urosevic M; Filonenko V; Osanai K; Moch H; Chen YT; Old LJ; Knuth A; Jaeger D
    Cancer Immunol Immunother; 2007 Feb; 56(2):249-58. PubMed ID: 16718472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients.
    Walton SM; Gerlinger M; de la Rosa O; Nuber N; Knights A; Gati A; Laumer M; Strauss L; Exner C; Schäfer N; Urosevic M; Dummer R; Tiercy JM; Mackensen A; Jaeger E; Lévy F; Knuth A; Jäger D; Zippelius A
    J Immunol; 2006 Dec; 177(11):8212-8. PubMed ID: 17114498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library.
    Jäger D; Stockert E; Jäger E; Güre AO; Scanlan MJ; Knuth A; Old LJ; Chen YT
    Cancer Res; 2000 Jul; 60(13):3584-91. PubMed ID: 10910072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
    Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
    Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
    Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
    J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
    Kudela P; Sun Z; Fourcade J; Janjic B; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2011 Jan; 186(1):312-22. PubMed ID: 21131422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses.
    Humer J; Waltenberger A; Grassauer A; Kurz M; Valencak J; Rapberger R; Hahn S; Löwer R; Wolff K; Bergmann M; Muster T; Mayer B; Pehamberger H
    Cancer Res; 2006 Feb; 66(3):1658-63. PubMed ID: 16452225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
    Jäger E; Stockert E; Zidianakis Z; Chen YT; Karbach J; Jäger D; Arand M; Ritter G; Old LJ; Knuth A
    Int J Cancer; 1999 Oct; 84(5):506-10. PubMed ID: 10502728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination for malignant melanoma: recent developments.
    Jäger D; Jäger E; Knuth A
    Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
    Houghton AN; Taormina MC; Ikeda H; Watanabe T; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4260-4. PubMed ID: 6933476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method.
    Nakatsura T; Senju S; Ito M; Nishimura Y; Itoh K
    Eur J Immunol; 2002 Mar; 32(3):826-36. PubMed ID: 11870627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
    Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
    Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
    J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
    J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
    Frøsig TM
    Dan Med J; 2015 Aug; 62(8):B5144. PubMed ID: 26239596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.